Abstract
Purpose: :
To compare changes in PED height and base diameter, as determined by Optical Coherence Tomography (OCT) after Intravitreal Bevacizumab or Ranibizumab injection for AMD.
Methods: :
22 cases of previously untreated eyes with PEDs associated with AMD were retrospectively evaluated. The Stratus OCT images were analyzed by one grader using a computerized graphical analysis program (Adobe Photoshop® 10). PED height and base diameter were measured prior to intravitreal drug injection and at various times following injection. The measurements were taken from the same OCT orientation (nasal to temporal, etc) for each case, and the orientation was chosen based on the largest PED height. Percent change in PED height and base diameter were determined by comparing each measurement to the baseline measurement. Three categories of PEDs, based on height [small(<25 um), medium(25-60 um), and large(>60 um)] were also evaluated for percent change in PED height and base diameter. Statistical analysis was performed using the Microsoft Excel® Data Analysis Stat Pack.
Results: :
Overall, PED height was reduced by 37% after injection of either Bevacicumab or Ranibizumab(p=0.03). Base diameter demonstrated a reduction of 20% after drug injection, but this was not statistically significant. Medium and Large PEDs demonstrated a height reduction by 40%(p=0.03) and 45%(0.015) respectively. Small PEDs showed a 28% reduction in height, but this was not statistically significant
Keywords: age-related macular degeneration • imaging/image analysis: clinical • retina